Dashboard
Manage Tickers

TNGX Tango Therapeutics, Inc.

Nasdaq tangotx.com


$ 8.77 $ -0.21 (-2.34 %)    

Wednesday, 22-Oct-2025 15:46:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.89 $ -5.94 (-0.97 %)
DIA $ 465.84 $ -3.38 (-0.72 %)
SPY $ 667.57 $ -4.35 (-0.65 %)
TLT $ 92.06 $ 0.07 (0.08 %)
GLD $ 377.51 $ 4.64 (1.24 %)
$ 8.99
$ 9.00
$ 8.76 x 5
$ 8.78 x 378
$ 8.37 - $ 9.12
$ 1.03 - $ 9.70
1,285,380
na
1B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

tango-therapeutics-to-showcase-initial-clinical-results-for-tng260-in-combination-with-pembrolizumab-in-stk11-mutant-lung-cancer-at-sitc-annual-meeting
Tango Therapeutics To Showcase Initial Cli...
10/06/2025 11:09:54

piper-sandler-initiates-coverage-on-tango-therapeutics-with-overweight-rating-announces-price-target-of-11
Piper Sandler Initiates Coverage On Tango ...
08/19/2025 11:51:28

Piper Sandler analyst Kelsey Goodwin initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and ann...

guggenheim-maintains-buy-on-tango-therapeutics-raises-price-target-to-10
Guggenheim Maintains Buy on Tango Therapeu...
08/06/2025 15:00:20

Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $8...

tango-therapeutics-q2-eps-035-beats-036-estimate-sales-3181m-miss-6679m-estimate
Tango Therapeutics Q2 EPS $(0.35) Beats $(...
08/05/2025 11:05:35

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

tango-therapeutics-doses-first-patient-in-phase-12-combo-trial-with-revolution-medicines-ras-inhibitors-for-mtap-deleted-cancers
Tango Therapeutics Doses First Patient In ...
06/27/2025 11:05:38

sarepta-therapeutics-kulr-technology-group-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Sarepta Therapeutics, KULR Technology Grou...
06/16/2025 12:38:15

quanex-building-products-manchester-united-byrna-technologies-and-other-big-stocks-moving-higher-on-friday
Quanex Building Products, Manchester Unite...
06/06/2025 14:20:02

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/29/2025 21:06:36

tango-therapeutics-announces-first-patient-dosed-in-tng456-phase-12-trial-in-patients-with-mtap-deleted-solid-tumors-with-focus-on-glioblastoma
Tango Therapeutics Announces First Patient...
05/21/2025 11:15:50

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of ...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
05/19/2025 17:05:59

tango-therapeutics-q1-eps-036-misses-035-estimate-sales-539m-miss-669m-estimate
Tango Therapeutics Q1 EPS $(0.36) Misses $...
05/12/2025 11:03:02

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of ...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

insights-into-tango-therapeuticss-upcoming-earnings
Insights into Tango Therapeutics's Upcomin...
05/09/2025 20:03:39

hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Tang...
04/14/2025 10:42:25

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...

tango-therapeutics-to-highlight-preclinical-data-on-precision-oncology-pipeline-with-five-posters-at-american-association-for-cancer-research-annual-meeting-2025
Tango Therapeutics To Highlight Preclinica...
03/25/2025 20:33:25

tango-therapeutics-q4-2024-gaap-eps-035-misses-034-estimate-sales-412m-miss-777m-estimate
Tango Therapeutics Q4 2024 GAAP EPS $(0.35...
02/27/2025 12:11:15

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of ...

unveiling-5-analyst-insights-on-tango-therapeutics
Unveiling 5 Analyst Insights On Tango Ther...
12/05/2024 15:01:50

cantor-fitzgerald-reiterates-overweight-on-tango-therapeuticsto-overweight
Cantor Fitzgerald Reiterates Overweight on...
12/05/2024 13:37:49

Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) from Overweight to Overweight.

tango-therapeutics-granted-fda-orphan-designation-status-for-small-molecule-inhibitor-of-prmt5-protein-arginine-methyl-transferase-5-treatment-of-pancreatic-cancer
Tango Therapeutics Granted FDA Orphan Desi...
11/27/2024 14:59:49

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1048724

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION